US2002128267A1PendingUtilityA1

Method of using COX-2 inhibitors in the treatment and prevention of ocular COX-2 mediated disorders

37
Priority: Jul 13, 2000Filed: May 4, 2001Published: Sep 12, 2002
Est. expiryJul 13, 2020(expired)· nominal 20-yr term from priority
Inventors:Rebanta BandyopadhyayDavid EvelethThomas Van HaarlemTugrul KararliSatish Singh
A61P 43/00A61P 41/00A61K 9/0048A61K 31/44A61P 27/10A61K 31/353A61K 31/465A61K 31/74A61K 31/38A61K 31/415A61K 31/435A61P 29/00A61K 31/50A61P 27/12A61P 27/02A61K 31/47A61K 45/06A61P 27/08A61K 31/12A61P 27/06A61P 25/04
37
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention provides methods for the treatment and prevention of ocular COX-2 mediated disorders using COX-2 inhibitors.

Claims

exact text as granted — not AI-modified
What is claimed is:  
     
         1 . A therapeutic method for treating or preventing an ocular COX-2 mediated disorder comprising administering an ocular COX-2 mediated disorder-effective amount of a source of a COX-2 inhibitor compound to a mammal in need of such treatment, wherein the disorder is selected from the group consisting of blepharitis, post-operative inflammation and pain from corneal transplant surgery, endophthalmitis, episcleritis, keratitis, keratoconjunctivitis, keratoconjunctivitis sicca, post-operative inflammation and pain from lens implantation surgery, Mooren's ulcer and post-operative inflammation and pain from retinal detachment surgery.  
     
     
         2 . The therapeutic method of  claim 1  wherein the source of the COX-2 inhibitor comprises a COX-2 inhibitor.  
     
     
         3 . The therapeutic method of  claim 2  wherein the COX-2 inhibitor is selected from the group consisting of celecoxib, deracoxib, valdecoxib, a benzopyran COX-2 inhibitor, rofecoxib, etoricoxib, 2-(3,5-difluorophenyl)-3-[4-(methylsulfonyl)phenyl]-2-cyclopenten-1-one and 2-(3,4-difluorophenyl)-4-(3-hydroxy-3-methylbutoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone.  
     
     
         4 . The therapeutic method of  claim 3  wherein the COX-2 inhibitor is celecoxib.  
     
     
         5 . The therapeutic method of  claim 3  wherein the COX-2 inhibitor is deracoxib.  
     
     
         6 . The therapeutic method of  claim 3  wherein the COX-2 inhibitor is valdecoxib.  
     
     
         7 . The therapeutic method of  claim 3  wherein the COX-2 inhibitor is a benzopyran COX-2 inhibitor.  
     
     
         8 . The therapeutic method of  claim 3  wherein the COX-2 inhibitor is rofecoxib.  
     
     
         9 . The therapeutic method of  claim 3  wherein the COX-2 inhibitor is etoricoxib.  
     
     
         10 . The therapeutic method of  claim 3  wherein the COX-2 inhibitor is 2-(3,5-difluorophenyl)-3-[4-(methylsulfonyl)phenyl]-2-cyclopenten-1-one.  
     
     
         11 . The therapeutic method of  claim 3  wherein the COX-2 inhibitor is 2-(3,4-difluorophenyl)-4-(3-hydroxy-3-methylbutoxy)-5-[4-(methylsulfonyl)phenyl]-3 (2H)-pyridazinone.  
     
     
         12 . The therapeutic method of  claim 1  wherein the source of the COX-2 inhibitor comprises a prodrug of a COX-2 inhibitor.  
     
     
         13 . The therapeutic method of  claim 12  wherein the prodrug of the COX-2 inhibitor is parecoxib.  
     
     
         14 . The therapeutic method of  claim 1  wherein the ocular COX-2 mediated disorder is Mooren's ulcer.  
     
     
         15 . The therapeutic method of  claim 14  wherein the source of the COX-2 inhibitor further comprises one or more ophthalmically acceptable excipient ingredients that reduce the rate of removal of the composition from the eye by lacrimation such that the composition has an effective residence time in the eye of about 2 to about 24 hours.  
     
     
         16 . A pharmaceutical composition for treating or preventing Mooren's ulcer, in a mammal in need of such treatment, consisting essentially of a source of a COX-2 inhibitor compound and one or more ophthalmically acceptable excipient ingredients that reduce the rate of removal of the composition from the eye by lacrimation such that the composition has an effective residence time in the eye of about 2 to about 24 hours.  
     
     
         17 . A therapeutic method for treating or preventing an ocular COX-2 mediated disorder comprising administering an ocular COX-2 mediated disorder-effective amount of celecoxib to a mammal in need of such treatment, wherein the disorder is selected from the group consisting of macular edema, intraoperative miosis and ocular pain.  
     
     
         18 . The therapeutic method of  claim 17  wherein the ocular COX-2 mediated disorder is macular edema.  
     
     
         19 . A therapeutic method for treating or preventing an ocular COX-2 mediated disorder comprising administering an ocular COX-2 mediated disorder-effective amount of deracoxib to a mammal in need of such treatment, wherein the disorder is selected from the group consisting of post-operative inflammation and pain from cataract surgery, acute injury to the eye tissue, glaucoma, macular edema, intraoperative miosis, ocular pain, photophobia, post-operative inflammation and pain from refractive surgery, retinitis, retinopathies and uveitis.  
     
     
         20 . The therapeutic method of  claim 19  wherein the ocular COX-2 mediated disorder is post-operative inflammation and pain from cataract surgery.  
     
     
         21 . The therapeutic method of  claim 20  wherein the ocular COX-2 mediated disorder is macular edema.  
     
     
         22 . A therapeutic method for treating or preventing an ocular COX-2 mediated disorder comprising administering an ocular COX-2 mediated disorder-effective amount of valdecoxib to a mammal in need of such treatment, wherein the disorder is selected from the group consisting of macular edema, intraoperative miosis and ocular pain.  
     
     
         23 . The therapeutic method of  claim 22  wherein the ocular COX-2 mediated disorder is macular edema.  
     
     
         24 . A therapeutic method for treating or preventing an ocular COX-2 mediated disorder comprising administering an ocular COX-2 mediated disorder-effective amount of a benzopyran COX-2 inhibitor to a mammal in need of such treatment, wherein the disorder is selected from the group consisting of glaucoma, macular edema, intraoperative miosis and ocular pain.  
     
     
         25 . The therapeutic method of  claim 24  wherein the ocular COX-2 mediated disorder is macular edema.  
     
     
         26 . A therapeutic method for treating or preventing an ocular COX-2 mediated disorder comprising administering an ocular COX-2 mediated disorder-effective amount of parecoxib to a mammal in need of such treatment, wherein the disorder is selected from the group consisting of conjunctivitis, glaucoma, macular edema, intraoperative miosis and ocular pain.  
     
     
         27 . The therapeutic method of  claim 26  wherein the ocular COX-2 mediated disorder is macular edema.  
     
     
         28 . A therapeutic method for treating or preventing an ocular COX-2 mediated disorder comprising administering an ocular COX-2 mediated disorder-effective amount of rofecoxib to a mammal in need of such treatment, wherein the disorder is selected from the group consisting of post-operative inflammation and pain from cataract surgery, conjunctivitis, acute injury to the eye tissue, glaucoma, macular edema, intraoperative miosis, ocular pain, photophobia, post-operative inflammation and pain from refractive surgery, retinitis, sarcoidosis and uveitis.  
     
     
         29 . The therapeutic method of  claim 28  wherein the ocular COX-2 mediated disorder is post-operative inflammation and pain from cataract surgery.  
     
     
         30 . The therapeutic method of  claim 28  wherein the ocular COX-2 mediated disorder is macular edema.  
     
     
         31 . A therapeutic method for treating or preventing an ocular COX-2 mediated disorder comprising administering an ocular COX-2 mediated disorder-effective amount of etoricoxib to a mammal in need of such treatment, wherein the disorder is selected from the group consisting of post-operative inflammation and pain from cataract surgery, conjunctivitis, acute injury to the eye tissue, macular edema, intraoperative miosis, ocular pain, photophobia, post-operative inflammation and pain from refractive surgery, retinitis, retinopathies, sarcoidosis and uveitis.  
     
     
         32 . The therapeutic method of  claim 31  wherein the ocular COX-2 mediated disorder is post-operative inflammation and pain from cataract surgery.  
     
     
         33 . The therapeutic method of  claim 31  wherein the ocular COX-2 mediated disorder is macular edema.  
     
     
         34 . A therapeutic method for treating or preventing an ocular COX-2 mediated disorder comprising administering an ocular COX-2 mediated disorder-effective amount of 2-(3,5-difluorophenyl)-3-[4-(methylsulfonyl)phenyl]-2-cyclopenten-1-one to a mammal in need of such treatment, wherein the disorder is selected from the group consisting of post-operative inflammation and pain from cataract surgery, conjunctivitis, acute injury to the eye tissue, macular edema, intraoperative miosis, ocular pain, photophobia, post-operative inflammation and pain from refractive surgery, retinitis, sarcoidosis and uveitis.  
     
     
         35 . The therapeutic method of  claim 34  wherein the ocular COX-2 mediated disorder is post-operative inflammation and pain from cataract surgery.  
     
     
         36 . The therapeutic method of  claim 34  wherein the ocular COX-2 mediated disorder is macular edema.  
     
     
         37 . A therapeutic method for treating or preventing an ocular COX-2 mediated disorder comprising administering an ocular COX-2 mediated disorder-effective amount of 2-(3,4-difluorophenyl)-4-(3-hydroxy-3-methylbutoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone to a mammal in need of such treatment, wherein the disorder is selected from the group consisting of post-operative inflammation and pain from cataract surgery, conjunctivitis, acute injury to the eye tissue, glaucoma, macular edema, intraoperative miosis, ocular pain, photophobia, post-operative inflammation and pain from refractive surgery, retinitis, retinopathies, sarcoidosis and uveitis.  
     
     
         38 . The therapeutic method of  claim 37  wherein the ocular COX-2 mediated disorder is post-operative inflammation and pain from cataract surgery.  
     
     
         39 . The therapeutic method of  claim 37  wherein the ocular COX-2 mediated disorder is macular edema.

Join the waitlist — get patent alerts

Track US2002128267A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.